{"id":11592,"date":"2021-08-30T17:23:18","date_gmt":"2021-08-30T15:23:18","guid":{"rendered":"https:\/\/iabnetz.de\/?post_type=publikationen&p=11592"},"modified":"2025-11-14T22:17:00","modified_gmt":"2025-11-14T21:17:00","slug":"modified-constraint-induced-movement-therapy-or-bimanual-occupational-therapy-following-injection-of-botulinum-toxin-a-to-improve-bimanual-performance-in-young-children-with-hemiplegic-cerebral-pal-88","status":"publish","type":"page","link":"https:\/\/relaunch.iabnetz.com\/en\/publikationen\/weitere-veroeffentlichungen\/modified-constraint-induced-movement-therapy-or-bimanual-occupational-therapy-following-injection-of-botulinum-toxin-a-to-improve-bimanual-performance-in-young-children-with-hemiplegic-cerebral-pal-88\/","title":{"rendered":"Sustained ef\ufb01cacy and safety of repeated incobotulinumtoxinA (Xeomin\u00ae) injections in blepharospasm: Truong D et al."},"content":{"rendered":"

<\/p>\n

\n
\n
<\/div>\n
\n
\n
NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES – ORIGINAL ARTICLE<\/div>\n
J Neural Transm<\/span><\/div>\n
DOI 10.1007\/s00702-013-0998-9<\/span><\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
<\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
Authors:<\/span><\/div>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
Daniel D. Truong\u00a0 \u00a0*<\/span><\/div>\n
Stephen M. Gollomp<\/span><\/div>\n
Joseph Jankovic<\/span><\/div>\n
Peter A. LeWitt<\/span><\/div>\n
Michael Marx<\/span><\/div>\n
Angelika Hanschmann<\/span><\/div>\n
Hubert H. Fernandez<\/span><\/div>\n
Xeomin US Blepharospasm Study Group<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
\u00a0<\/a><\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

\n

Author Details:<\/p>\n

\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
D. D. Truong (*)\u00a0 \u00a0<\/span>& <\/span>The Parkinson\u2019s and Movement Disorder Institute, <\/span>9940 Talbert Avenue, Fountain Valley, California 92708, USA<\/span><\/div>\n
e-mail:\u00a0dtruong@pmdi.org<\/span><\/span><\/div>\n
S. M. Gollomp <\/span>Division of Neurology, Lankenau Hospital, <\/span>Wynnewood, PA, USA<\/span><\/div>\n
J. Jankovic <\/span>The Parkinson\u2019s Disease and Movement Disorders Clinic, <\/span>Department of Neurology, Baylor College of Medicine, <\/span>Houston, TX,\u00a0<\/span><\/div>\n
USA<\/span><\/div>\n
P. A. LeWitt <\/span>Department of Neurology, Henry Ford Hospital, <\/span>Detroit, MI, USA<\/span><\/div>\n
M. Marx &\u00a0<\/span> A. Hanschmann <\/span>Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany<\/span><\/div>\n
H. H. Fernandez <\/span>Movement Disorders, Center for Neurological Restoration, <\/span>Cleveland Clinic, Cleveland, OH, USA<\/span><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n
<\/div>\n
\n
\n

Please click here!<\/a><\/p>\n<\/div>\n<\/div>\n

<\/p>","protected":false},"excerpt":{"rendered":"

Abstract: IncobotulinumtoxinA (Xeomin\u00ae, NT 201) is a puri\ufb01ed botulinum toxin type A free from accessory (complexing) proteins. …<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":30426,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template-full-width.php","meta":{"_acf_changed":false,"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"class_list":["post-11592","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/11592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/comments?post=11592"}],"version-history":[{"count":1,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/11592\/revisions"}],"predecessor-version":[{"id":30644,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/11592\/revisions\/30644"}],"up":[{"embeddable":true,"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/pages\/30426"}],"wp:attachment":[{"href":"https:\/\/relaunch.iabnetz.com\/en\/wp-json\/wp\/v2\/media?parent=11592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}